KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Income (2016 - 2025)

Historic Operating Income for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$8.7 million.

  • Arbutus Biopharma's Operating Income rose 5961.29% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year increase of 4370.11%. This contributed to the annual value of -$76.3 million for FY2024, which is 228.42% up from last year.
  • Arbutus Biopharma's Operating Income amounted to -$8.7 million in Q3 2025, which was up 5961.29% from $1.5 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Operating Income high stood at $1.5 million for Q2 2025, and its period low was -$25.7 million during Q1 2025.
  • Over the past 5 years, Arbutus Biopharma's median Operating Income value was -$18.4 million (recorded in 2021), while the average stood at -$17.2 million.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 5867.51% in 2023, then skyrocketed by 10689.43% in 2025.
  • Arbutus Biopharma's Operating Income (Quarter) stood at -$20.8 million in 2021, then fell by 8.49% to -$22.6 million in 2022, then rose by 8.04% to -$20.7 million in 2023, then surged by 32.84% to -$13.9 million in 2024, then surged by 37.85% to -$8.7 million in 2025.
  • Its Operating Income was -$8.7 million in Q3 2025, compared to $1.5 million in Q2 2025 and -$25.7 million in Q1 2025.